New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 3, 2014
06:34 EDTJAZZJazz Pharmaceuticals trades at attractive risk/reward, says Piper Jaffray
Piper Jaffray believes Jazz Pharmaceuticals' acquisition of the U.S. rights to Defitelio makes the company's long-term growth story even more attractive. Piper says Jazz shares trade at an attractive risk/reward and it reiterates an Overweight rating on the name with a $200 price target.
News For JAZZ From The Last 14 Days
Check below for free stories on JAZZ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 16, 2014
11:51 EDTJAZZOECD looks to close tax loopholes with new proposals
Subscribe for More Information
September 8, 2014
08:17 EDTJAZZJazz Pharmaceuticals executing on all cylinders, says Stifel
Following management meetings, Stifel reiterates its Buy rating and $195 price target on Jazz Pharmaceuticals given growth opportunities and sustainability of its current portfolio. The firm agrees with the Xyrem franchise expansion strategies through new patient capture near-term, and longer-term, the addition of complementary wakefulness products.
07:21 EDTJAZZJazz looks more attractive for Allergan than Salix, says Wells Fargo
Subscribe for More Information
September 5, 2014
11:40 EDTJAZZJazz Pharmaceuticals calls active on renewed takeover speculation
Subscribe for More Information
11:00 EDTJAZZRumor: Jazz Pharmaceuticals strength attributed to renewed takeover speculation
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use